Resveratrol analogue 4,4′-dihydroxy-trans-stilbene potently inhibits cancer invasion and metastasis

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Savio, Monica ^a   Ferraro, Daniela ^a   MacCario, Cristina ^a   Vaccarone, Rita ^a   Jensen, Lasse D ^b,c   Corana, Federica ^a   Mannucci, Barbara ^a   Bianchi, Livia ^a   Cao, Yihai ^b   Stivala, Lucia Anna ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b KAROLINSKA INSTITUTE   (Sweden)

^c LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

4,4'-DIHYDROXYSTILBENE; RESVERATROL; STILBENE DERIVATIVE;

ANIMAL; APOPTOSIS; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; HUMAN; LUNG NEOPLASMS; MALE; METABOLISM; MOUSE; NEOPLASMS, EXPERIMENTAL; PATHOLOGY; TUMOR INVASION; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; APOPTOSIS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LUNG NEOPLASMS; MALE; MICE; NEOPLASM INVASIVENESS; NEOPLASMS, EXPERIMENTAL; STILBENES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84956602859     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep19973     Document Type: Article

References (52)

1. Fulda, S. Resveratrol and derivatives for the prevention and treatment of cancer. Drug Discov Today 15, 757-765 (2010).
2. Carter, L. G., D'Orazio, J. A., Pearson, K. J. Resveratrol and cancer: focus on in vivo evidence. Endocr Relat Cancer 21, R209-225 (2014).
3. Aggarwal, B. B. et al. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 24, 2783-2840 (2004).
4. Bishayee, A. Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev Res (Phila) 2, 409-418 (2009).
5. Jang, M. et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275, 218-220 (1997).
6. Stivala, L. A. et al. Specific structural determinants are responsible for the antioxidant activity and the cell cycle effects of resveratrol. J Biol Chem 276, 22586-22594 (2001).
7. Szewczuk, L. M., Forti, L., Stivala, L. A., Penning, T. M. Resveratrol is a peroxidase-mediated inactivator of COX-1 but not COX-2: a mechanistic approach to the design of COX-1 selective agents. J Biol Chem 279, 22727-22737 (2004).
8. Antus, C. et al. Anti-inflammatory effects of a triple-bond resveratrol analog: structure and function relationship. Eur J Pharmacol 748, 61-67 (2015).
9. Savio, M. et al. The resveratrol analogue 4,4-dihydroxy-trans-stilbene inhibits cell proliferation with higher efficiency but different mechanism from resveratrol. Int J Biochem Cell Biol 41, 2493-2502 (2009).
10. Belleri, M. et al. Antiangiogenic and vascular-targeting activity of the microtubule-destabilizing trans-resveratrol derivative 3,5,4-trimethoxystilbene. Mol Pharmacol 67, 1451-1459 (2005).
11. Paulitschke, V. et al. 3,3 ,4,4 ,5,5-hexahydroxystilbene impairs melanoma progression in a metastatic mouse model. J Invest Dermatol 130, 1668-1679 (2010).
12. Pan, Z. et al. Identification of molecular pathways affected by pterostilbene, a natural dimethylether analog of resveratrol. BMC Med Genomics 1, 7-20 (2008).
13. Maccario, C. et al. The resveratrol analog 4,4-dihydroxy-trans-stilbene suppresses transformation in normal mouse fibroblasts and inhibits proliferation and invasion of human breast cancer cells. Carcinogenesis 33, 2172-80 (2012).
14. Sinsheimer, J. E., Smith, R. V. Metabolic hydroxylations of trans-stilbene. Biochem J 111, 35-41 (1969).
15. Sanoh, S., Kitamura, S., Sugihara, K., Ohta, S. Cytochrome P450 1A1/2 mediated metabolism of trans-stilbene in rats and humans. Biol Pharm Bull 25, 397-400 (2002).
16. Sugihara, K. et al. Metabolic activation of the proestrogens trans-stilbene and trans-stilbene oxide by rat liver microsomes. Toxicol Appl Pharmacol 167, 46-54 (2000).
17. Torres, P. et al. Antioxidant and insect growth regulatory activities of stilbenes and extracts from Yucca periculosa. Phytochemistry 64, 463-473 (2003).
18. Fang, H. et al. Structure-activity relationships for a large diverse set of natural, synthetic, and environmental estrogens. Chem Res Toxicol 14, 280-294 (2001).
19. Balan, K. V. et al. Proteasome-independent down-regulation of estrogen receptor-alpha (ERalpha) in breast cancer cells treated with 4,4-dihydroxy-trans-stilbene. Biochem Pharmacol 72, 573-581 (2006).
20. Stojanovi, S., Sprinz, H., Brede, O. Efficiency and mechanism of the antioxidant action of trans-resveratrol and its analogues in the radical liposome oxidation. Arch Biochem Biophys 391, 79-89 (2001).
21. Fang, J. G. et al. Antioxidant effects of resveratrol and its analogues against the free-radical-induced peroxidation of linoleic acid in micelles. Chemistry 8, 4191-4198 (2002).
22. Cai, Y. J., Fang, J. G., Ma, L. P., Yang, L., Liu, Z. L. Inhibition of free radical-induced peroxidation of rat liver microsomes by resveratrol and its analogues. Biochim Biophys Acta 1637, 31-38 (2003).
23. Privat, C. et al. Antioxidant properties of trans-epsilon-viniferin as compared to stilbene derivatives in aqueous and nonaqueous media. J Agric Food Chem 50, 1213-1217 (2002).
24. Fan, G. J. et al. 4,4-Dihydroxy-trans-stilbene, a resveratrol analogue, exhibited enhanced antioxidant activity and cytotoxicity. Bioorg Med Chem 17, 2360-2365 (2009).
25. Tang, J. J. et al. Finding more active antioxidants and cancer chemoprevention agents by elongating the conjugated links of resveratrol. Free Radic Biol Med 50, 1447-1457 (2011).
26. Kimura, Y., Sumiyoshi, M., Baba, K. Antitumor activities of synthetic and natural stilbenes through antiangiogenic action. Cancer Sci 99, 2083-2096 (2008).
27. Tomé-Carneiro, J. et al. Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence. Curr Pharm Des 19, 6064-6093 (2013).
28. Cai, Y. C. et al. Ant i-tumor act ivity and mechanisms of a novel vascular disrupting agent, (Z)-3,4 ,5-trimethoxylstilbene-3-O-phosphate disodium (M410). Invest New Drugs 29, 300-311 (2011).
29. Aldawsari, F. S., Velázquez-Martínez, C. A. 3,4 ,5-trans-Trimethoxystilbene; a natural analogue of resveratrol with enhanced anticancer potency. Invest New Drugs 33, 775-786 (2015).
30. Kubben, F. J. et al. Proliferating cell nuclear antigen (PCNA): a new marker to study human colonic cell proliferation. Gut 35, 530-535 (1994).
31. Sennino, B., McDonald, D. M. Controlling escape from angiogenesis inhibitors. Nat Rev Cancer 12, 699-709 (2012).
32. Kimura, Y., Okuda, H. Resveratrol isolated from Polygonum cuspidatum root prevents tumor growth and metastasis to lung and tumor-induced neovascularization in Lewis lung carcinoma-bearing mice. J Nutr 131, 1844-1849 (2001).
33. Chen, W., Yeo, S. C., Elhennawy, M. G., Xiang, X., Lin, H. S. Determination of naturally occurring resveratrol analog trans-4,4-dihydroxystilbene in rat plasma by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study. Anal Bioanal Chem 407, 5793-5801 (2015).
34. Muzzio, M. et al. Determination of resveratrol and its sulfate and glucuronide metabolites in plasma by LC-MS/MS and their pharmacokinetics in dogs. J Pharm Biomed Anal 59, 201-208 (2012).
35. Gescher, A. J., Steward, W. P. Relationship between mechanisms, bioavailibility, and preclinical chemopreventive efficacy of resveratrol: a conundrum. Cancer Epidemiol Biomarkers Prev 12, 953-957 (2003).
36. Meng, X., Maliakal, P., Lu, H., Lee, M. J., Yang, C. S. Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice. J Agric Food Chem 52, 935-942 (2004).
37. Walle, T., Hsieh, F., DeLegge, M. H., Oatis, J. E., Walle, U. K. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 32, 1377-1382 (2004).
38. Murakami, I. et al. Metabolism of skin-absorbed resveratrol into its glucuronized form in mouse skin. PLoS One 9, e115359 (2014).
39. Wen, X., Walle, T. Methylated flavonoids have greatly improved intestinal absorption and metabolic stability. Drug Metab Dispos 34 1786-1792 (2006).
40. McCormack, D., McFadden, D. Pterostilbene and cancer: current review. J Surg Res 173, e53-61 (2012).
41. Rimando, A. M. et al. Cancer chemopreventive and antioxidant activities of pterostilbene, a naturally occurring analogue of resveratrol. J Agric Food Chem 50, 3453-3457 (2002).
42. Kapetanovic, I. M., Muzzio, M., Huang, Z., Thompson, T. N., McCormick, D. L. Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother Pharmacol 68, 593-601 (2011).
43. Das, S., Lin, H. S., Ho, P. C., Ng, K. Y. The impact of aqueous solubility and dose on the pharmacokinetic profiles of resveratrol. Pharm Res 25, 2593-2600 (2008).
44. Lee, E. O. et al. Potent inhibition of Lewis lung cancer growth by heyneanol A from the roots of Vitis amurensis through apoptotic and anti-angiogenic activities. Carcinogenesis 27, 2059-2069 (2006).
45. Brakenhielm, E., Cao, R., Cao, Y. Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes. FASEB J 15, 1798-1800 (2001).
46. Locatelli, G. A. et al. Inhibition of mammalian DNA polymerases by resveratrol: mechanism and structural determinants. Biochem J 389, 259-268 (2005).
47. Coppa, T. et al. Structure-activity relationship of resveratrol and its analogue, 4,4-dihydroxy-trans-stilbene, toward the endothelin axis in human endothelial cells. J Med Food 14, 1173-1180 (2011).
48. Giansanti, V. et al. Study of the effects of a new pyrazolecarboxamide: changes in mitochondria and induction of apoptosis. Int J Biochem Cell Biol 41, 1890-1898 (2009).
49. Lazze, M. C. et al. Anthocyanins induce cell cycle perturbations and apoptosis in different human cell lines. Carcinogenesis 25, 1427-1433 (2004).
50. Fenoglio, C. et al. Renal fibrogenesis and platinum compounds in a rat model: a novel Pt (II) complex vs. cisplatin. Anticancer Res 35, 739-751 (2015).
51. Zhang, D. et al. Antiangiogenic agents significantly improve survival in tumor-bearing mice by increasing tolerance to chemotherapy-induced toxicity. Proc Natl Acad Sci USA 108, 4117-4122 (2011).
52. Yang, X. et al. VEGF-B promotes cancer metastasis through a VEGF-A-independent mechanism and serves as a marker of poor prognosis for cancer patients. Proc Natl Acad Sci USA 112, E2900-2909 (2015).